Literature DB >> 26697472

Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome.

Irfana Muqbil1, Ramzi M Mohammad1.   

Abstract

Entities:  

Year:  2015        PMID： 26697472      PMCID： PMC4669332          DOI： 10.3978/j.issn.2305-5839.2015.09.15

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  15 in total

1.  Bcl-2: B cell life, death and neoplasia.

Authors:  S J Korsmeyer; T J McDonnell; G Nunez; D Hockenbery; R Young
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

Review 2.  BCL-2: found bound and drugged!

Authors:  Anthony Letai
Journal:  Trends Mol Med       Date:  2005-10       Impact factor: 11.951

3.  Programmed anuclear cell death delimits platelet life span.

Authors:  Kylie D Mason; Marina R Carpinelli; Jamie I Fletcher; Janelle E Collinge; Adrienne A Hilton; Sarah Ellis; Priscilla N Kelly; Paul G Ekert; Donald Metcalf; Andrew W Roberts; David C S Huang; Benjamin T Kile
Journal:  Cell       Date:  2007-03-23       Impact factor: 41.582

4.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.

Authors:  Leena Gandhi; D Ross Camidge; Moacyr Ribeiro de Oliveira; Philip Bonomi; David Gandara; Divis Khaira; Christine L Hann; Evelyn M McKeegan; Elizabeth Litvinovich; Philip M Hemken; Caroline Dive; Sari H Enschede; Cathy Nolan; Yi-Lin Chiu; Todd Busman; Hao Xiong; Andrew P Krivoshik; Rod Humerickhouse; Geoffrey I Shapiro; Charles M Rudin
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

5.  Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Authors:  Joel D Leverson; Darren C Phillips; Michael J Mitten; Erwin R Boghaert; Dolores Diaz; Stephen K Tahir; Lisa D Belmont; Paul Nimmer; Yu Xiao; Xiaoju Max Ma; Kym N Lowes; Peter Kovar; Jun Chen; Sha Jin; Morey Smith; John Xue; Haichao Zhang; Anatol Oleksijew; Terrance J Magoc; Kedar S Vaidya; Daniel H Albert; Jacqueline M Tarrant; Nghi La; Le Wang; Zhi-Fu Tao; Michael D Wendt; Deepak Sampath; Saul H Rosenberg; Chris Tse; David C S Huang; Wayne J Fairbrother; Steven W Elmore; Andrew J Souers
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

6.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

Authors:  G S Choudhary; S Al-Harbi; S Mazumder; B T Hill; M R Smith; J Bodo; E D Hsi; A Almasan
Journal:  Cell Death Dis       Date:  2015-01-15       Impact factor: 8.469

7.  Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.

Authors:  Alan A Arnold; Amro Aboukameel; Jianyong Chen; Dajun Yang; Shaomeng Wang; Ayad Al-Katib; Ramzi M Mohammad
Journal:  Mol Cancer       Date:  2008-02-14       Impact factor: 27.401

8.  SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status.

Authors:  Ayad M Al-Katib; Yuan Sun; Anton Scott Goustin; Asfar Sohail Azmi; Ben Chen; Amro Aboukameel; Ramzi M Mohammad
Journal:  J Hematol Oncol       Date:  2009-02-16       Impact factor: 17.388

9.  A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.

Authors:  Anthony W Tolcher; Wendi V Rodrigueza; Drew W Rasco; Amita Patnaik; Kyriakos P Papadopoulos; Alex Amaya; Timothy D Moore; Shari K Gaylor; Charles L Bisgaier; Mina P Sooch; Michael J Woolliscroft; Richard A Messmann
Journal:  Cancer Chemother Pharmacol       Date:  2013-12-03       Impact factor: 3.333

10.  Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide.

Authors:  Wendi V Rodrigueza; Michael J Woolliscroft; Abdul-Shukkur Ebrahim; Robert Forgey; Patrick J McGovren; Gerold Endert; Andreas Wagner; Danielle Holewa; Amro Aboukameel; Richard D Gill; Charles L Bisgaier; Richard A Messmann; Christopher E Whitehead; Elzbieta Izbicka; Robert Streeper; Michael C Wick; Gabriela Stiegler; C A Stein; David Monsma; Craig Webb; Mina P Sooch; Steffen Panzner; Ramzi Mohammad; Neal C Goodwin; Ayad Al-Katib
Journal:  Cancer Chemother Pharmacol       Date:  2014-05-16       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.